Severity of psoriasis and its impact on patient-reported outcomes (PROs): real world evidence with brodalumab 210 mg from the LIBERO study

Severity of psoriasis and its impact on patient-reported outcomes (PROs): real world evidence with brodalumab 210 mg from the LIBERO study

Aim Only limited data is available on the benefit of brodalumab 210 mg, an IL-17 receptor A antagonist, on patient-reported outcomes (PROs) in different psoriasis severity groups under real-world-evidence (RWE) conditions.Methods LIBERO, a prospective, multicenter, 12- and 52-weeks (W) non-intervent...

Full description

Saved in:
Bibliographic Details
Main Authors: Matthias Augustin, Rudolf E. Schopf, Sven R. Quist, Nalan Kalyon, Ralph M. von Kiedrowski
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Journal of Dermatological Treatment
Subjects:
IL-17RA antagonist
non-interventional study
patient-reported outcomes (PROs)
patient needs
patient benefits
quality of life
Online Access:https://www.tandfonline.com/doi/10.1080/09546634.2025.2500511
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/09546634.2025.2500511

Similar Items